Previous 10 | Next 10 |
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”...
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and it...
2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible th...
2023-11-09 14:56:37 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Ironwood Pharmaceuticals: The Right Play Now Ironwood ...
2023-11-09 10:39:02 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Offi...
2023-11-09 07:03:18 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals Q3 2023 Earnings Preview JMP starts Ironwood at market outperform, cites potent...
– LINZESS ® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year – – Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in shor...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $0.17 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duol...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with...